Skip to content
#software testing Open access

Establishment of epidemiological cut-off values of cefotaxime-sulbactam against Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Serratia marcescens, Acinetobacter baumannii and Staphylococcus aureus

Sep 2026 · Frontiers in Microbiology · Vol 17 · 0 citations · 28 references
Medicine

TL;DR

ECOFFs of cefotaxime–sulbactam were established for seven clinically important bacterial species and provide essential reference values for distinguishing wild-type from non-wild-type isolates and support future breakpoint-setting and antimicrobial resistance surveillance.

Abstract

Objective To establish the epidemiological cut-off (ECOFF) value of cefotaxime-sulbactam against Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Serratia marcescens, Acinetobacter baumannii, and Staphylococcus aureus. Methods A total of 1,770 non-duplicate clinical isolates were collected from five laboratories in four cities in China. Minimum inhibitory concentrations (MICs) of cefotaxime-sulbactam were determined independently using the broth microdilution method according to EUCAST standards. For A. baumannii, cefotaxime-sulbactam was tested at a 2:1 ratio, whereas for the other species sulbactam was tested at a fixed concentration of 4 mg/L. ECOFFs were determined using ECOFFinder software and visual estimation following EUCAST principles. Results Statistical endpoints at 95%, 97.5%, 99%, 99.5%, and 99.9% were calculated. The final ECOFFs were assigned based on concordance between ECOFFinder-derived estimates and visual inspection, using the 99% endpoint as the primary statistical estimate. The ECOFFs were 0.25/4 mg/L for E. coli and K. pneumoniae; 0.5/4 mg/L for E. cloacae; 0.06/4 mg/L for P. mirabilis; 1/4 mg/L for S. marcescens; 4/4 mg/L for S. aureus; and 4/2 mg/L for A. baumannii. Conclusion ECOFFs of cefotaxime–sulbactam were established for seven clinically important bacterial species. These results provide essential reference values for distinguishing wild-type from non-wild-type isolates and support future breakpoint-setting and antimicrobial resistance surveillance.

Read PDF

Similar papers

Open access Sep 2026

Determination of Antibiotic Resistance and ESBL, AmpC, and Carbapenemase Activities of Bacteria Isolated from the Kızılırmak River

Objective: This study aimed to determine the antibiotic resistance profiles and the phenotypic and genotypic activities of extended-spectrum β-lactamases (ESBLs), AmpC, and carbapenemases in bacteria isolated from water samples collected from the Kızılırmak River. Methods: Water samples were collected aseptically from...

S. Kızıl, Gamze İmre, Edanur Çelik et al. · 0 citations
Open access Aug 2026

Superior in vitro Activity of Cefepime-Enmetazobactam Over Ceftazidime-Avibactam and Piperacillin-Tazobactam Against 3rd Generation cephalosporin resistant Enterobacterales.

The rise of extended-spectrum β-lactamase (ESBL) and carbapenem-resistant Enterobacterales (CRE) has severely limited treatment options in India. Cefepime-enmetazobactam (FPE), a novel β-lactam/β-lactamase inhibitor combination approved by the US FDA in 2024, shows promise as a carbapenem-sparing agent. A total of 383...

P. Aggarwal, S. Saxena, Anugula Amritha et al. · 0 citations
Open access Oct 2026

Biapenem–fosfomycin shows enhanced in vitro activity compared with meropenem–fosfomycin against NDM-producing Enterobacterales

ABSTRACT Treatment options for New Delhi metallo-β-lactamase-producing Enterobacterales (NDME) remain limited, and the clinical relevance of fosfomycin–carbapenem combinations has not been fully established. We evaluated whether biapenem–fosfomycin provides greater in vitro activity than meropenem–fosfomycin. A total o...

Takashi Okanda, Daishu Fukushima, Natsuki Yumura et al. · 0 citations
Sep 2026

Distribution of ceftazidime-avibactam and colistin MIC values in carbapenem-resistant Klebsiella pneumoniae and its association with carbapenemase genotypes in Can Tho, Vietnam.

Carbapenem-resistant Klebsiella pneumoniae (CRKP) is a World Health Organization critical-priority pathogen, with a bloodstream-infection mortality of 40-70%. Ceftazidime-avibactam (CAZ-AVI) and colistin are key agents against CRKP, yet data on their minimum inhibitory concentrations (MICs) and association with carbape...

Hai Nguyen, Bình Đình Trần, Y. Nguyen et al. · 0 citations
Open access Oct 2026

Ceftazidime-avibactam activity against urinary carbapenem resistance Escherichia coli and Klebsiella pneumoniae isolates

Background and Objectives: Urinary tract infections (UTIs) are among the most prevalent bacterial infections in women, with Escherichia coli and Klebsiella pneumoniae as leading causative pathogens. The emergence of multidrug-resistant (MDR) and carbapenem-resistant strains poses a significant therapeutic challenge. Ce...

Siavosh Salmanzadeh Ahrabi, Farzaneh Salehinejad, Masoud Sokhanvar-Mahani · 0 citations

Related blog posts

Microsoft Research Blog Oct 30, 2026

From synthetic enterprise data evaluations to real Microsoft Copilot AI confidence

Evaluating Microsoft Copilot at enterprise scale requires test data that captures the full complexity of real organizations, yet real enterprise data contains sensitive information that cannot be used for evaluation under any circumstances. The post From synthetic enterprise data evaluations to real Microsoft Copilot AI confidence appeared first on Microsoft Research.

Microsoft Research Blog Oct 29, 2026

Microsoft Research Focus – Edition #97

Host Sowbhagya Suresh shares some of the latest news and cutting-edge research from across Microsoft—from understanding the challenges facing coding agents to uncovering how people use AI at work and improving extended-range weather forecasting. The post Microsoft Research Focus – Edition #97 appeared first on Microsoft Research.

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.